Health

Sleep Matters: What Apnea Studies Teach Us About Brain Health

Published

5 years ago

February 14, 2021

Do you ever wake up feeling tired? Have you been told that you snore? If so, you may have obstructive sleep apnea, one of the most common sleep disorders among adults. One of two major types of sleep apnea, obstructive apnea occurs when you stop breathing while asleep because something is blocking your airway, and it can be very dangerous to sufferers. And, interestingly, the impact of sleep apnea on health can be quite extensive. As recent studies of both obstructive and central sleep apnea demonstrate, the condition may be linked to memory problems and may even mimic Alzheimer’s disease’s impact on the brain.

Sleep Apnea: The Basics

We know that obstructive sleep apnea is very common among adults, but we don’t have particularly good data on the condition, with estimates ranging from 9-38%. However, we do know that men, older adults, and overweight individuals are more likely to suffer from this form of sleep apnea.

Central sleep apnea, a form of the condition characterized by the failure of the brain to trigger breathing during sleep, is more commonly linked to other health conditions, ranging from congestive heart failure to various neurological diseases, and may occur at any age. For example, children with Angelman syndrome are prone to both central and obstructive sleep apnea, as are young people with Prader-Willi syndrome.

Sleep And The Brain

Sleep is an important function of the brain, and our brain’s activity changes immensely while we sleep. When we don’t get enough sleep, or sleep poorly, though, the consequences extend far beyond simple fatigue. Given this, scientists studying the impact of sleep, or a lack thereof, on the brain have turned to obstructive sleep apnea patients as a sample group, and one thing they’ve discovered is that many people with obstructive sleep apnea demonstrate the same brain changes seen in Alzheimer’s patients, despite the fact that they were never diagnosed with any form of dementia.

Making Connections

Even before this study of sleep apnea patients, it was clear to researchers and doctors that Alzheimer’s and other forms of dementia were closely linked to sleep, and particularly to circadian rhythm disorders. As recent brain research has shown, Alzheimer’s patients often experience serious sleep disruption, which can cause them to get up and wander in the middle of the night and can complicate their care. Further research into the vulnerability of the primary circadian clock gene (Clk) to neurodegenerative disease is still underway.

Other Theories And Research Avenues

In addition to the research showing neurofibrillary tangles and beta-amyloid plaques in sleep apnea patients’ brains, ongoing work seeks to understand why these develop in this patient set. One working hypothesis suggests that insufficient deep sleep among obstructive sleep apnea patients may interfere with the body’s ability to clear beta-amyloid and other waste from the brain. Looking ahead, if researchers can determine why these patients develop plaques but do not develop dementia symptoms, this could offer valuable insights for the treatment of Alzheimer’s disease and related disorders.

Patients often dismiss sleep apnea as snoring or as a condition that just makes them feel a little tired, but the more we learn about it, the more concerning the long-term effects of this condition become. Just as researchers are taking the condition seriously as a topic of study, then, patients must take its management serious to mitigate its medical consequences.

Health

BioLongevity Labs: How Two Biohackers Are Making Longevity Safe for the Mainstream

Published

2 weeks ago

February 18, 2026

Michelle Langton

Humans have been looking for ways to extend their lifespan for hundreds of years. Medicine has made impressive strides, but for many, the effects of aging are still painfully real.

Through BioLongevity Labs, biohackers and entrepreneurs Jay Campbell and Josh Felber aim to introduce ordinary people to potentially life-changing compounds called peptides. Campbell and Felber come from very different backgrounds.

Campbell is a five-time international bestselling author and globally recognized leader in the health-optimization space. Felber is a serial entrepreneur who excels at scaling businesses.

For both men, BioLongevity Labs is more than just a business venture — it’s about helping everyday people discover something that just might prolong and improve their lives.

“Your body inevitably changes as the years pile on,” says Campbell. “Your energy drops, and wrinkles start showing up uninvited. Peptides can change everything.”

Many people have probably heard the term “peptide” in passing. Some may know they’re associated with longevity. Most people just don’t have a strong grasp of how they work.

A peptide is a short chain of amino acids, which are the building blocks of proteins. Essentially, peptides are like shorter, simpler proteins. That might sound unremarkable, but the real magic of peptides lies in how they work.

They function as signaling or “messenger” molecules telling the body to perform specific functions. Many peptides function similarly to hormones. A relevant example is GLP-1 (glucagon-like peptide-1) receptor agonists. This class of medications includes semaglutide and tirzepatide, two wildly popular weight-loss drugs.

“These peptides aren’t just another biohacking fad,” Campbell explains. “They enhance insulin secretion and suppress glucagon release to balance blood sugar levels and promote sustainable weight loss”. But what sets GLP-1 receptor agonists apart is their ability to regulate hunger.

Through the reduction of appetite and increased feelings of fullness, it is far easier for dieters to stick to a calorie deficit.” Although GLP-1 receptor agonists are widely prescribed, most peptides aren’t.

Campbell asserts, because many peptides have the potential to cure illnesses by treating the fundamental root cause, they go against America’s “sick care” model of healthcare. They potentially threaten drug companies and their bottom line.

“Peptides are simultaneously a dream come true for mankind and the worst possible nightmare for the pharmaceutical industry,” says Campbell. “It’s not a conspiracy theory. It’s pure economics and psychology in action. People will do whatever it takes to make as much money as possible in a free-market society, even if it means suppressing a superior solution.”

Patients probably aren’t going to be introduced to peptides through the healthcare system. Many discover them on their own. But for the many people who don’t have a solid understanding of how they work molecularly or even what dose to take, there is a risk. That’s precisely what BioLongevity Labs’ co-founders are attempting to address.

Jay Campbell has dedicated his life to educating people about therapeutic peptides and optimized hormones, and along with his partner Josh Felber, they’ve created a company offering filler-free, third-party tested peptides and bioregulators.

Campbell and Felber stress the fact that BioLongevity Labs isn’t meant to be a replacement for traditional medical care. Instead, its products bridge the gap between clinical and extra-clinical care. There’s no magic pill or single solution to solve the problem of aging.

But thanks to the development of specialized peptides, bioregulators, and small molecules, we’re closer than we’ve ever been before.